clinical trial · NCT07221513
Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension
HFrEF - Heart Failure With Reduced Ejection FractionHFpEF - Heart Failure With Preserved Ejection FractionGroup 2 Pulmonary HypertensionJK07
brief summary
This is a Phase 2a, open-label, multiple-dose study to assess the safety, tolerability, and efficacy of JK07 in participants 18 to 85 years of age with diagnosed HF and cpcPH. At least 20 and up to approximately 30 participants will be enrolled and receive JK07 high dose in this open-label trial.
started
Dec 15, 2025
primary completion
Sep 1, 2026
completion
Oct 1, 2027
last updated
Jan 20, 2026
official title
A Phase 2a, Open-Label Study to Assess the Safety, Tolerability, and Efficacy of JK07 in Participants With Heart Failure and Group 2 Combined Post-Capillary and Pre-Capillary Pulmonary Hypertension (RENEU-PH)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol